Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corporation has demonstrated significant revenue growth in its glaucoma segment, reporting third-quarter revenues of $110 million, exceeding consensus estimates and reflecting a robust 45% increase from the previous quarter. The company's operating margin has notably improved to (7.0%), representing a substantial year-over-year increase of 1,210 basis points and surpassing analyst expectations. Additionally, Glaukos's Corneal Health segment has maintained a strong compound annual growth rate of approximately 15.2% worldwide since 2020, indicating positive momentum and future growth potential for its innovative therapies.

Bears say

Glaukos Corp is experiencing challenges that have resulted in a negative outlook for its stock, primarily due to depressed sales and lower growth rates in its Corneal Health segment, which has seen a compounded annual growth rate (CAGR) decline to approximately 8.9% worldwide over the past three years. The company faces additional risks from slower adoption of its innovative products, such as the iDose and iStent infinite, as well as increasing competition from emerging market entrants that could hinder overall market growth. Furthermore, anticipated declines in revenues from its Legacy Surgical Glaucoma segment, alongside potential changes in reimbursement policies and delayed product launches, contribute to an uncertain financial trajectory for Glaukos.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.